Spear Bio secures FDA breakthrough device designation for its novel pTau 217 blood test, advancing scalable solutions for early Alzheimer’s disease diagnosis

Spear Bio Inc., a biotechnology company pioneering next-generation ultra-sensitive immunoassays, today announced that its pTau 217 blood test has been granted Breakthrough Device Designation by the U.S. Food and Drug…

Continue ReadingSpear Bio secures FDA breakthrough device designation for its novel pTau 217 blood test, advancing scalable solutions for early Alzheimer’s disease diagnosis